Recorded Webinar with Morey Kraus: Perinatal Stem Cells from Umbilical Cord Tissue and Their Potential Use in Newborns with Hypoxic Ischemic Injuries
Share the Science
Watch the recorded webinar to hear Morey Kraus, chief scientific officer at PerkinElmer Diagnostics and ViaCord, discuss perinatal stem cells, potential applications of these stem cells in regenerative medicine, and their potential use in newborns with hypoxic ischemic injuries.
This webinar provides an understanding of what perinatal stem cells are and are not as well as methods of isolation, characterization, and storage; including the characterization of different sources and types of stem cells available in the umbilical vein and cord itself, such as hematopoietic, mesenchymal, and mixed heterogeneous stem cells. Methods of isolation and storage, including enzyme digestion and whole tissue cryopreservation, are also discussed. Mr. Kraus reviews matching principles, which may increase the utility of collections for haploidentical family members and the potential of regenerative medicine applications of perinatal stem cells from cord tissue.
Regenerative medicine applications of perinatal stem cells from cord tissue may include autoimmune disorders, sports injuries, and organ damage. The proposition of using perinatal stem cells alone or in combination with cord blood in autologous or related allogeneic clinical studies is likely to be dependent on their availability for newborns and children with acute medical challenges involving the lung, gut, and brain. Applications in lung disorders may include bronchopulmonary dysplasia, asthma, and severe allergies. Gut disorders may include necrotizing enterocolitis and Crohns; and brain disorders may include hypoxic ischemic encephalopathy and cerebral palsy. A review of data from several animal models distinguishing the biological potential of these stem cells in animal models, including hypoxic ischemic injury, are included.
You Will Learn:
- What perivascular stem cells from cord tissue are and are not
- Methods of isolation, characterization, and storage
- Potential applications of these stem cells in regenerative medicine
- About pre-clinical proof of principle studies in animal models, including a model of newborn hypoxic ischemic injury
Morey Kraus discusses umbilical cord stem cells and their potential use in newborns with hypoxic ischemic injuries.
Morey Kraus is the Chief Scientific Officer of the Diagnostics division of PerkinElmer, Inc. where he oversees scientific affairs for the maternal fetal health business, including ViaCord. Morey was the founder, chairman and Chief Executive Officer of t. Breeders, a cellular therapy company focused on stem cell expansion technologies for clinical transplantation. ViaCord, a family cord blood bank, was acquired in 2000 and t. Breeders was renamed ViaCell, where Morey served as the Chief Technology Officer until the company was acquired by PerkinElmer in 2007. Morey was a Ph.D. candidate at Worcester Polytechnic Institute in an interdisciplinary Bioprocess Engineering Program combining Chemical Engineering and Biotechnology. He holds a B.A. in comparative religion from American University in Washington, D.C.
Morey has published multiple articles in various peer-reviewed journals on topics ranging from the expansion of umbilical cord blood stem cells for clinical use to the in vivo homing of uncultured and selectively amplified cord blood stem cells. In addition, he is the inventor or co-inventor on seven issued patents.
Mediware and Save the Cord Foundation are proud to bring you this exclusive speaker series to discuss the topics you and your peers are most interested in. Join us as we feature your colleagues to discuss their latest research, opinions on industry news and so much more. We look forward to having you on board for this exciting series!